The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- 18F-PSMA-1007
- Conditions
- Prostate Cancer
- Sponsor
- Affiliated Hospital of Jiangnan University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- 18F-PSMA-1007 PET/CT and 18F-FDG PCT/CT imaging were compared to determine the advantages of 18F-PSMA-PSMA PET/CT imaging for prostate cancer
- Status
- Enrolling By Invitation
- Last Updated
- last year
Overview
Brief Summary
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.
Detailed Description
1. Visual analysis of images: describe the location, size, shape and degree of uptake of lesions; 2. Semi-quantitative analysis: the ratio of lesion site uptake to liver uptake was measured by area of interest method (ROI); 3. Comparative analysis: Compared with clinical routine 18F-FDG PET/CT imaging, the advantages of PSMA PET/CT imaging were clarified; 4. Evaluation and analysis of efficacy: before and after treatment, to clarify the early treatment evaluation value of PSMA PET/CT imaging, and compare it with 18F-FDG PET/CT imaging; 5. Prognostic study: Through multi-factor analysis, the relationship between the level of PSMA PET/CT imaging uptake and the prognosis of patients was clarified.
Investigators
Chunjing Yu
Director
Affiliated Hospital of Jiangnan University
Eligibility Criteria
Inclusion Criteria
- •Prostate cancer is clinically suspected. The patient was diagnosed with prostate cancer by biopsy. Prostate cancer needs to be evaluated after treatment.
Exclusion Criteria
- •Patients who did not meet the requirements as assessed by the investigator.
Arms & Interventions
18F-PSMA-1007
Subjects: Patients with suspected or diagnosed prostate cancer, or biochemical recurrence of prostate cancer. Over 40 years old (including 40 years old); Informed consent and access to follow-up; To exclude patients who are difficult to receive further diagnosis and treatment because of their serious condition. PSMA PET/CT was reviewed 7 days and 3 months after surgery. All patients were followed up once every 3 months to understand the progression and survival of the lesions.
Intervention: 18F-PSMA-1007
18F-FDG
The corresponding patients underwent PSMAPET/CT examination within one week before and after routine 18F-FDGPCT/CT imaging (control examination). PCT/CT whole body scan was performed 45min-1h after intravenous injection of the developer, and the image processing was as usual.
Intervention: 18F-FDG
Outcomes
Primary Outcomes
18F-PSMA-1007 PET/CT and 18F-FDG PCT/CT imaging were compared to determine the advantages of 18F-PSMA-PSMA PET/CT imaging for prostate cancer
Time Frame: 1 day
For patients receiving 18F-PSMA-1007 PET/CT, 18F-FDG PET/CT imaging was performed, and image visual analysis, semi-quantitative analysis and prognostic study were performed on PET/CT images. To evaluate the diagnosis, staging and prognosis of 18F-PSMA-1007